ImmuPharma (LON:IMM) Trading Up 129% – Time to Buy?

ImmuPharma plc (LON:IMM) shares rose 129% during trading on Monday . The stock traded as high as GBX 6.90 ($0.09) and last traded at GBX 5.35 ($0.07). Approximately 50,843,520 shares were traded during mid-day trading, an increase of 708% from the average daily volume of 6,295,439 shares. The stock had previously closed at GBX 2.34 ($0.03).

ImmuPharma Stock Performance

The company has a 50 day moving average price of GBX 1.99 and a 200 day moving average price of GBX 2.65. The company has a market capitalization of £20.78 million, a price-to-earnings ratio of -831.67 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.